Decreased Circulating T Regulatory Cells in Egyptian Patients with Nonsegmental Vitiligo: Correlation with Disease Activity by Doaa Salah Hegab, Mohamed Attia Saad Attia

“…Effective Treg cell-based immunotherapies might be a future hope for patients with progressive vitiligo.…”
Get full text

Vector‐Free Deep Tissue Targeting of DNA/RNA Therapeutics via Single Capacitive Discharge Conductivity‐Clamped Gene Electrotransfer by Jeremy L. Pinyon, Georg vonJonquieres, Stephen L. Mow, Amr Al Abed, Keng‐Yin Lai, Mathumathi Manoharan, Edward N. Crawford, Stanley H. Xue, Sarah Smith‐Moore, Lisa J. Caproni, Sarah Milsom, Matthias Klugmann, Nigel H. Lovell, Gary D. Housley

“…The findings support adoption of SCD‐CC‐GET for vaccines and immunotherapies, and extend the utility of this technology to meet the demand for efficient vector‐free, precision, deep tissue delivery of NA therapeutics.…”
Get full text

A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration by Ryunosuke Oyama, Akira Nabeshima, Makoto Endo, Alexey Novikov, Toshifumi Fujiwara, Capucine Phelip, Nobuhiko Yokoyama, Yoshinao Oda, Martine Caroff, Yoshihiro Matsumoto, Jerome Kerzerho, Yasuharu Nakashima

“…Abstract Background Osteosarcoma is the most common malignant bone tumour with limited treatment options and poor outcomes in advanced metastatic cases. Current immunotherapies show limited efficacy, highlighting the need for novel therapeutic approaches. …”
Get full text

Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings by Shyam Kumar Mishra, Tanzina Akter, Umme Laila Urmi, George Enninful, Manjulatha Sara, Jiawei Shen, Dittu Suresh, Liangjun Zheng, Elias Shiferaw Mekonen, Binod Rayamajhee, Francesco M. Labricciosa, Massimo Sartelli, Mark Willcox

“…Previous studies have not comprehensively discussed the advantages and limitations of various strategies, including bacteriophage therapy, probiotics, immunotherapies, photodynamic therapy, essential oils, nanoparticles and antimicrobial peptides (AMPs) within a single review. …”
Get full text

Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation by Ilka Knippertz, Andrea Deinzer, Jan Dörrie, Niels Schaft, Dirk M. Nettelbeck, Alexander Steinkasserer

“…Therefore, this modular promoter system represents a promising tool for future DC-based immunotherapies in vivo.…”
Get full text

Harnessing the immunomodulatory potential of natural products in precision medicine—a comprehensive review by Maya G. Pillai, Helen Antony

“…Clinical applications of NP-based immunotherapies, such as curcumin and resveratrol in cancer treatment, highlight their diverse pharmacological properties. …”
Get full text

Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines by Aziz A. Chentoufi, Jeffrey B. Ulmer, Lbachir BenMohamed

Get full text

Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications by Wanlei Wei, Traian Sulea

“…While there is a justified need for pH-dependent immunotherapies, current engineering techniques are tedious and laborious, requiring repeated rounds of experiments under different pH conditions. …”
Get full text

Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β by Rebecca Faresjö, Elisabet O. Sjöström, Tiffany Dallas, Magnus M. Berglund, Jonas Eriksson, Dag Sehlin, Stina Syvänen

“…Neurodegenerative diseases such as Alzheimer’s disease (AD) pose substantial challenges to patients and health-care systems, particularly in countries with aging populations. Immunotherapies, including the marketed antibodies lecanemab (Leqembi®) and donanemab (KisunlaTM), offer promise but face hurdles due to limited delivery across the blood–brain barrier (BBB). …”
Get full text

A New Antibody–Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia by Michela Flego, Mauro Andreotti, Francesca Romana Mauro, Maria Beatrice Arasi, Silvia Zamboni, Zuleika Michelini, Sara Pepe, Clementina Maria Galluzzo, Roberta Amici, Diego Moricoli, Chiara Mazzei, Alessandro Ascione, Alessandra Mallano

“…The preliminary data presented in this work suggest that IL15’s targeting of NK cells via scFvB1 potentiates the effects of IL15 and that scFvB1IL15 can be a useful agent for overcoming NK functional gaps and contribute to NK-cell-based immunotherapies.…”
Get full text

Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer by Nirmala Ghimirey, Chase Steele, Brian J. Czerniecki, Gary K. Koski, Loral E. Showalter

“…Although immune-based therapies have made remarkable inroads in cancer treatment, they usually must be combined with standard treatment modalities, including cytotoxic drugs, to achieve maximal clinical benefits. As immunotherapies are further advanced and refined, considerable efforts will be required to identify combination therapies that will maximize clinical responses while simultaneously decreasing the unpleasant and sometimes life-threatening side effects of standard therapy. …”
Get full text

Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance by Hussein Sabit, Borros Arneth, Timothy M. Pawlik, Shaimaa Abdel-Ghany, Aysha Ghazy, Rawan M. Abdelazeem, Amany Alqosaibi, Ibtesam S. Al-Dhuayan, Jawaher Almulhim, Noof A. Alrabiah, Ahmed Hashash

“…Future studies examining specific metabolic pathways and targeting approaches to reduce the heterogeneity in the TME will likely lead to better outcomes with immunotherapies, drug delivery, etc., for cancer treatments. …”
Get full text

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy by Barbara D. Friedes, Amanda M. DiNofia, Emma Iannone, Yimei Li, Susan R. Rheingold, Allison Barz Leahy, Lisa Wray, Colleen Callahan, Diane Baniewicz, Lauren Vernau, Kelly D. Getz, Richard Aplenc, Shannon L. Maude, Stephan A. Grupp, Regina M. Myers

Get full text

The Effect of Tumor Angiogenesis Agents on Tumor Growth Dynamics: A Mathematical Model by Ali Mohseni, Mohammad Pooyan, Somayeh Raiesdana, Mohammad Bagher Menhaj

“…Conclusion: Our results show the ineffectiveness of targeted treatments on the immune system, which has been confirmed by many negative treatment methods in immunotherapies. Tumor-secreted inhibitor factors are essential to regulating the angiogenesis process. …”
Get full text

A Journey into the Complexity of Temporo-Insular Gliomas: Case Report and Literature Review by Manuel De Jesus Encarnacion Ramirez, Gervith Reyes Soto, Carlos Castillo Rangel

“…Ongoing research into targeted therapies, immunotherapies, and innovative technologies remains critical to advancing patient care and improving long-term prognosis.…”
Get full text

Colon Cancer Genetic and Epigenetic Changes, Etiopathogenesis, Risk Factors, Treatment: Literature Review by Gabrielė Ūbaitė, Aurelija Remeikaitė, Justas Žilinskas

“…It highlights the potential of CRISPR/Cas9, immunotherapies, and liquid biopsies in pioneering personalized CRC treatments and early detection. …”
Get full text

Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural c... by Louis-Emmanuel Chriqui, Etienne Abdelnour-Berchtold, Edoardo Zanfrini, Severine Devesa-Perez, Michel Gonzalez, Thorsten Krueger, Kim Ellefsen, Alice Destaillats, David Bonnet, Martin Hübner, Hasna Bouchaab, Michal Bassani-Sternberg, Solange Peters, Sabrina Cavin, Jean Y Perentes

“…If proven safe, PITHAC could be combined with systemic immunotherapies for the management of cancer. Trial registration: ClinicalTrials.gov Identifier: NCT06281860…”
Get full text

Dynamic changes in peripheral blood lymphocyte trajectory predict the clinical outcomes of sepsis by Dongkai Li, Jiahui Zhang, Wei Cheng, Guoyu Zhao, Xianli Lei, Yawen Xie, Na Cui, Hao Wang

“…Incorporating longitudinal trajectory modeling and lymphocyte subsets may improve prognostic risk assessment and guide the selection of immunotherapies tailored to specific immune phenotypes in sepsis patients.Clinical trial registrationhttps://www.chictr.org.cn/showproj.aspx?…”
Get full text

Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody by Eva Schlein, Ken G. Andersson, Tiffany Dallas, Stina Syvänen, Dag Sehlin

“…Recent development of amyloid-β (Aβ)-targeted immunotherapies for Alzheimer’s disease (AD) have highlighted the need for accurate diagnostic methods. …”
Get full text

The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience by Qian Zheng, Qian Zheng, Qian Zheng, Di Shao, Jin Shu, Jin Shu, Jin Shu, Qin Zhang, Qin Zhang, Qin Zhang, Min Huang, Dong Wang, Dong Wang, Dong Wang, Dongling Zou, Dongling Zou, Dongling Zou

“…Conclusively, large-scale NGS has revolutionized EC management by facilitating rapid molecular subtype identification, guiding tailored adjuvant therapies, targeted treatments, and immunotherapies, and efficiently screening for Lynch syndrome, thereby significantly improving patient outcomes.…”
Get full text